Financial Contrast: Atossa Genetics (ATOS) versus SeaSpine (SPNE)

Atossa Genetics (NASDAQ: ATOS) and SeaSpine (NASDAQ:SPNE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Insider & Institutional Ownership

48.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 46.1% of SeaSpine shares are owned by institutional investors. 5.6% of Atossa Genetics shares are owned by insiders. Comparatively, 13.5% of SeaSpine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.


This table compares Atossa Genetics and SeaSpine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atossa Genetics N/A -186.36% -145.47%
SeaSpine -21.75% -27.65% -21.65%

Risk & Volatility

Atossa Genetics has a beta of 3.35, indicating that its share price is 235% more volatile than the S&P 500. Comparatively, SeaSpine has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Atossa Genetics and SeaSpine, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics 0 0 1 0 3.00
SeaSpine 0 0 5 0 3.00

Atossa Genetics currently has a consensus target price of $10.00, suggesting a potential upside of 338.60%. SeaSpine has a consensus target price of $18.00, suggesting a potential upside of 29.50%. Given Atossa Genetics’ higher possible upside, equities analysts clearly believe Atossa Genetics is more favorable than SeaSpine.

Earnings and Valuation

This table compares Atossa Genetics and SeaSpine’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atossa Genetics N/A N/A -$8.12 million N/A N/A
SeaSpine $131.81 million 1.55 -$32.11 million ($2.58) -5.39

Atossa Genetics has higher earnings, but lower revenue than SeaSpine.

About Atossa Genetics

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

About SeaSpine

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers orthobiologics products in various forms, such as putties, pastes, strips, and resorbable mesh. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in minimally invasive, complex, deformity, and degenerative procedures. The company was incorporated in 2015 and is headquartered in Carlsbad, California.

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.

Leave a Reply